342417-02-1

Basic information

• Product Name: Methyl (6-(4-Methylpiperazin-1-yl)-4-(o-tolyl)pyridin-3-yl)carbaMate
• Synonyms: Methyl (6-(4-Methylpiperazin-1-yl)-4-(o-tolyl)pyridin-3-yl)carbaMate;[6-(4-methyl-piperazin-1-yl)-4-o-tolylpyridin-3-yl]-carbamic acid methyl ester
• CAS NO: 342417-02-1
• Molecular Formula: C₁₉H₂₄N₄O₂
• Molecular Weight: 340.41946
• Mol File: 342417-02-1.mol
• Article Data: 7

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Methyl (6-(4-Methylpiperazin-1-yl)-4-(o-tolyl)pyridin-3-yl)carbaMate(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl (6-(4-Methylpiperazin-1-yl)-4-(o-tolyl)pyridin-3-yl)carbaMate(342417-02-1)
• EPA Substance Registry System: Methyl (6-(4-Methylpiperazin-1-yl)-4-(o-tolyl)pyridin-3-yl)carbaMate(342417-02-1)

Safety Data

• Hazardous Substances Data: 342417-02-1(Hazardous Substances Data)

Usage

General Description

Methyl (6-(4-Methylpiperazin-1-yl)-4-(o-tolyl)pyridin-3-yl)carbaMate is a chemical compound with a complex molecular structure that includes a methyl group, a piperazine ring, a pyridine ring, and a carbamate group. It is a synthetic compound that may have potential pharmaceutical applications due to its unique structure and potential interactions with biological systems. The presence of the piperazine and pyridine rings suggests that it may have an affinity for certain biological receptors or enzymes, and the carbamate group may contribute to its stability and solubility. Further research and testing would be needed to fully understand the potential uses and effects of this compound.

Upstream product

• 109-01-3 1-methyl-piperazine 
• 58757-38-3 6-Chloronicotinoyl chloride 
• 70625-63-7 methyl 2-cyano-3-(2-methylphenyl)-2-propenoate 
• 529-20-4 2-methylphenyl aldehyde 
• 873443-66-4 3-cyano-2,6-dichloro-4-(2-methylphenyl)pyridine 
• 115309-58-5 N-tert-butyl-6-chloro-nicotinamide 
• 5326-23-8 6-Chloro-3-pyridinecarboxylic acid 
• 342417-01-0 4-(2-methylphenyl)-6-(4-methylpiperazinyl)-3-pyridinecarboxamide 
• 33872-80-9 o-tolyl magnesium chloride 
• 881743-64-2 N-tert-butyl-6-(4-methylpiperazin-1-yl)-4-(o-tolyl)nicotinamide 
• 342417-04-3 N-tert-butyl-6-chloro-4-(o-tolyl)nicotinamide 
• 342416-99-3 6-chloro-4-o-tolyl-nicotinic acid 
• 342417-00-9 6-chloro-4-(o-tolyl)nicotinamide 
• 124-41-4 sodium methylate 

Downstream Products

• 1431216-61-3 1-(5-(2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethylpropanamido)-4-(o-tolyl)pyridin-2-yl)-4-methylpiperazine 1,4-dioxide 
• 1431216-68-0 4-(5-{2-[3,5-bis(trifluoromethyl)phenyl]-N,2-dimethylpropanamido}-4-(o-tolyl)pyridin-2-yl)-1-methyl-1-{[bis(tert-butoxy)phosphoryl]oxymethyl}piperazin-1-ium 
• 1431216-59-9 4-(5-(2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethylpropanamido)-4-(o-tolyl)pyridin-2-yl)-1-methyl-1-((phosphonooxy)methyl)piperazin-1-ium 
• 290297-25-5 methyl-[6-(4-methyl-piperazin-1-yl)-4-o-tolyl-pyridin-3-yl]-amine 
• 290297-26-6 netupitant 

Relevant articles and documents

NK1 receptor-targeting antagonist and application of same to chemotherapy-induced nausea and vomiting

The invention relates to a NK1 receptor-targeting antagonist and application of the same to chemotherapy-induced nausea and vomiting, belonging to the technical field of adjuvant therapeutics for tumor chemotherapy. The invention provides a compound as shown in a formula I which is described in the specification, or a racemate, stereoisomer, tautomer, isotopic label, oxynitride or pharmaceutically-acceptable salt thereof. The invention also provides a preparation method for the compound, a pharmaceutical compositions and the application of the compound or the racemate, stereoisomer, tautomer,isotopic label, oxynitride or pharmaceutically-acceptable salt thereof.

Substituted 4-phenyl pyridines having anti-emetic effect

Disclosed are compounds, compositions and methods for the prevention and/or treatment of diseases which are pathophysiologically mediated by the neurokinin (NK1) receptor. The compounds have the general formula (I):

Research and development of an efficient process for the construction of the 2,4,5-substituted pyridines of NK-1 receptor antagonists

Roche has identified a 2,4,5-trisubstituted pyridine template for a new class of potent NK1 receptor antagonists. Previous strategies for construction of the pyridine core of these NK-1 receptor antagonists involved functionalization of a 2,5-disubstituted pyridine. We now report on construction of the pyridine core from commodity components. Shestopalov reported the synthesis of trans-4′-aryl-5′-cyano-1′,2′,3′, 4′-tetrahydro-6′-hydroxy-2′-oxo-1,3′-bipyridinium inner salts from 1-(2-amino-2-oxo-ethyl)pyridinium chloride, aromatic aldehydes, and ethyl cyanoacetate in the presence of a base. Reaction of these salts with phosphorus oxychloride affords 4-aryl-3-cyano-2,6-dichloropyridines. These are efficiently converted to nicotinamide precursors of the Roche NK-1 receptor antagonists by regioselective displacement of one chlorine by an amine, hydrogenolysis of the remaining chlorine, and nitrile hydrolysis.